固本抑瘤Ⅱ号方对抗癌药物的增效作用

ENHANCED ANTITUMOR EFFECT OF ANTICANCER DRUGS BY GUBENYILIU PRESCRIPTION NoⅡ(GUB)

作者测定了固本抑瘤Ⅱ号方（下称固本）加上抗癌药（ＣＴＸ，５－Ｆｕ和ＡＤＭ）抗小鼠肿瘤Ｓ—１８０和肝癌生长的影响。结果表明，单用固本对小鼠肿瘤Ｓ—１８０和肝癌（Ｈｅｐａ）无明显的抑瘤作用。固本与抗癌药联用时，６０ｇ·ｋｇ－１／ｄ的固本能显著增强ＣＴＸ，５－ＦＵ抗小鼠Ｓ—１８０和肝癌的作用（金正均法ｑ值均＞１）；但不能增强ＡＤＭ抗小鼠Ｓ—１８０的作用（ｑ值（１）。而１２０ｇ·ｋｇ－１／ｄ对ＣＴＸ抗Ｓ—１８０和肝癌有一定的增强作用，但疗效不稳定（３／５次实验的ｑ值＞１）。提示固本的增效作用要求的剂量是在６０～１２０ｇ·ｋｇ－１／ｄ。固本在增加抗癌药物疗效的同时，各联合用药组的荷瘤小鼠未见有明显的毒性增加表现。

The enhanced antitumor activity of CTX,5-FU and ADM against Sarcoma -180(S-180)and Hepatoma(Hep) in mice by GUB was studied.The results showed that GUB itself possessed no signifi-cant antitumor activity on S-180 and Hep in mice at doses 40-120g/kg-1·d-1, but it markedly potentiat-ed the antitumor activity of 5-FU and CTX on S-180 and Hep(q>0.85 by Dr.Jin Jing-jun’s formula),but the antitumpr effect of ADM on S-180 was not enhanced by GUB. Our experiments showed that GUBat the doses of 60～120g/kg-1·d-1 can enhance the antitumor activity of 5-FU and CTX,but it did notpotentiate the toxicity of 5-FU and CTX.